Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Sections
Personal tools
Log in
 
You are here: Home › Protocols › Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase II

Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase II

1015
Kinsinger, Chris — National Cancer Institute

No involved investigator sites defined.

The objective of the "System Suitability (CompRef) Study" was to validate mass spectrometry protocols used at each Proteome Characterization Center (PCC).


The objective of the "System Suitability (CompRef) Study" was to validate mass spectrometry protocols used at each Proteome Characterization Center (PCC).

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement